The role of iron in cancer

European Journal of Cancer Prevention

Volumn 5, Issue 1, 1996, Pages 19-36

  Weinberg, E D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Cancer; Iron; Iron chelation; Iron overload; Iron withholding

Indexed keywords

DEFEROXAMINE; FERRITIN; GALLIUM NITRATE; HYDROXYL RADICAL; IRON; NITRIC OXIDE;

ANIMAL EXPERIMENT; CANCER; CANCER CELL; CANCER PATIENT; CARCINOGENESIS; HUMAN; INTOXICATION; IRON OVERLOAD; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; CARCINOGENS; CARRIER PROTEINS; CELL DIVISION; FERRITINS; HUMANS; HYDROXYL RADICAL; IMMUNITY, CELLULAR; IRON; IRON-BINDING PROTEINS; MACROPHAGES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; RECEPTORS, TRANSFERRIN; TRANSFERRIN-BINDING PROTEINS;

EID: 0030040395     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (204)

1. Abbott M, Galloway A, Cunningham JI. (1985). Haemochromatosis presenting with a double yersinia infection. J Infec 13: 143-5.
2. Adams PC (1994). Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. Am J Hematol 45: 146-9.
3. Adams PC, Gregor J (1990). Hemochromatosis and yersiniosis. Can J Gastroenterol 4: 160-2.
4. Ainsworth MA, Hogan DL, Koss MA, Isenberg JI (1993). Cigarette smoking inhibits acid-stimulated duodenal mucosal bicarbonate secretion. Ann Intern Med 119: 882-6.
5. Aisen P (1988). Iron metabolism in isolated liver cells. Ann NY Acad Sci 576: 93-9.
6. Akiba S, Neriishi K, Blot WJ et al (1991). Serum ferritin and stomach cancer risk among a Japanese population. Cancer 61: 1707-12.
7. Ammann RW, Müller E, Bansky J, Schüller G, Häcki WH (1980). High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand J Gastroenterol 15: 733-6.
8. Antoine D, Braun P, Cervoni P, Schwartz P, Lamy P (1979). Le cancer bronique des mineurs de fer de Lorraine peut-il être consideré comme une maladie professionelle? Rev Fr Mal Respir 7: 63-5.
9. Bacon BR, Britton RS (1990). The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 11: 127-37.
10. Badawi AF, Mostafa MH, Probert A, O'Connor PJ (1995). Role of schistosomiasis in bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogensis. Eur J Cancer Prev 4: 45-59.
11. Basset P, Quesnau Y, Zwiller J (1986). Iron-induced L1210 cell growth: evidence of a transferrin-independent iron transport. Cancer Res 46: 1644-7.
12. Berman JJ (1988). Cell proliferation and the aetiology of hepatocellular carcinoma. J Hepatol 7: 305-9.
13. Birgens HS (1994). The monocytic receptor for lactoferrin and its involvement in lactoferrin-mediated iron transport. In Lactoferrin, Structure and Function (eds Hutchens TW et al); Plenum Press, New York, pp. 99-105.
14. Biscegli AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT (1988). Hepatocellular carcinoma. Ann Intern Med 108: 390-401.
15. Blot WJ, Brown LM, Pottern LM, Stone BJ, Fraumeni JR Jr (1983). Lung cancer among long-term steel workers. Am J Epidemiol 117: 706-15.
16. Blumberg BS, Lustbader ED, Whitford PL (1981). Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA 78: 3222-4.
17. Bochenek WJ, Koronczewski R (1973). Effects of cigarette smoking on bicarbonate and volume of duodenal contents. Am J Dig Dis 18: 729-33.
18. Bomford A, Williams R (1976). Long term results of venesection therapy in idiopathic haemochromatosis. Quart J Med 45: 611-23.
19. Boshoff C, Whitby D, Hatzlioannou T et al (1995). Kaposi's sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345: 1043-4.
20. Boyd JT, Doll R, Faulds JS, Leiper J (1970). Cancer of the lung in iron ore (haematite) miners. Br J Indust Med 27: 97-105.
21. Bradbear RA, Bain C, Siskind V et al (1985). Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 75: 81-4.
22. Brown JP, Hewick RM, Hellström KE, Doolittle RF, Dreyer WJ (1982). Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature 296: 171-3.
23. Brown RK, McBurney A, Lunec J, Kelly FJ (1995). Oxidative damage to DNA in patients with cystic fibrosis. Free Rad Biol Med 18: 801-6.
24. Campbell JA (1940). Effects of precipitated silica and of iron oxide on the incidence of primary lung tumors in mice. Br Med J 2: 275-80.
25. Carbone D (1992). Smoking and cancer. Am J Med 93 Suppl 1A: 13S-7S.
26. Carter RL (1969). Early development of injection-site sarcomas in rats. Br J Cancer 23: 559-66.
27. Cazzola M, Bergamaschi G, Dezza L, Arosio P (1990). Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75: 1903-19.
28. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S (1982). Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 27: 909-16.
29. Chitambar CR, Narasimhan J (1991). Targetting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 59: 3-10.
30. Cope GF, Wyatt JI, Heatly RV, Pinder IF (1991). Alcohol consumption in patients with colorectal adenomatous polyps. Gut 32: 70-2.
31. Corday JL, Weber G, Bury T, Mariz S, Roelandts I, Radermecker MF (1992). Iron content in human alveolar macrophages. Eur Resp J 5: 804-9.
32. Crosby WH (1987). Hemochromatosis: current concepts and management. Hosp Pract 22: 173-92.
33. Crosby WH (1988). Unsolved problems in hemochromatosis. Ann NY Acad Sci 528: 323-7.
34. Deiss A (1983). Iron metabolism in reticuloendothelial cells. Semin Hematol 20: 81-90.
35. de Sousa M (1989). The immunology of iron overload. In Iron in Immunity, Cancer and Inflammation (eds de Sousa M, Brock JH); J Wiley, Chichester, pp. 247-58.
36. de Sousa M, Potaznik D (1984). Proteins of the metabolism of iron, cells of the immune system and malignancy. In Vitamins, Nutrition and Cancer (ed Prasad A); Karger, Basel, pp. 231-9.
37. Djeha A, Brock JH (1992). Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol 80: 235-41.
38. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L (1990). Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50: 4929-30.
39. Dörner MH, Abel U, Fritz D, Manke H-G, Drings F (1983). Serum ferritin in relation to the course of Hodgkin's disease. Cancer 52: 2308-12.
40. Drapier J-C, Hibbs JB Jr (1986). Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. J Clin Invest 78: 790-7.
41. Dreyfus JR (1936). Lungencarcinoma bei Geschwistern nach Inhalation von eisenoxydaltigem Staub in der Jugend. Zeit Klin Med 130: 256-60.
42. Dumont AE, Ford RJ, Becker FF (1976). Siderosis of lymph nodes in patients with Hodgkin's disease. Cancer 38: 1247-52.
43. Edling C (1982). Lung cancer and smoking in a group of iron ore miners. Am J Indust Med 3: 191-9.
44. El Boulhany MN, Ghoneim MA, Mansour MA (1972). Carcinoma of the bilharzial bladder in Egypt. Br J Urol 44: 561-4.
45. Ellaurie M, Rubinstein A (1994). Ferritin levels in pediatric HIV-1 infection. Acta Paediatr 83: 1035-7.
46. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann H-WL (1987). Prognostic factors in neuroblastoma. Cancer 59: 1853-9.
47. Faux SP, Howden PJ, Levy LS (1994). Iron-dependent formation of 8-hydroxydeoxyguanosine in isolated DNA and mutagenicity in Salmonella typhimurium TA102 induced by crocidolite. Carcinogenesis 15: 1749-51.
48. Freudenheim JL, Graham S, Marshall JR, Haughey BP, Wilkinson G (1990). A case-control study of diet and rectal cancer in western New York. Am J Epidemiol 131: 612-24.
49. Friedman GD, Van den Eeden SK (1993). Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol 22: 30-7.
50. Furst A (1960). Metals in tumors. In Metal Binding in Medicine (eds Seven MJ, Johnson LA); J B Lippincott, Philadelphia, p. 346.
51. Gangaidzo IT, Gordeuk VR (1995). Hepatocellular carcinoma and African iron overload. Gut 37: 727-30.
52. Garcia JGN, Dodson RF, Callahan KS (1989). Effect of environmental particulates on cultured human and bovine endothelium. Lab Invest 61: 53-61.
53. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1992). Intake of fat, meat and fiber in relation to risk of colon cancer in men. Cancer Res 54: 2390-7.
54. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Askin JE, Bothwell TH (1993). African iron overload as a risk factor for hepatoma and TB. Blood 82: 482a.
55. Graf E, Eaton JW (1985). Dietary suppression of colonic cancer: fiber or phytate? Cancer 56: 717-8.
56. Granger DL, Lehninger AL (1982). Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol 95: 527-35.
57. Granger DL, Hibbs JB Jr, Perfect JR, Durack DT (1990). Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 85: 264-73.
58. Green R, Esparza I, Schreiber R (1988). Iron inhibits the non-specific tumorcidal activity of macrophages. Ann NY Acad Sci 526: 301-9.
59. Greenberg G (1976). Sarcomata have developed after intramuscular injections of iron. Br Med J 1: 1508-9.
60. Haddow A, Hornung FS (1960). On the carcinogenicity of an iron dextran complex. J Natl Cancer Inst 24: 109-27.
61. Haddow A, Roe JFC, Mitchley BCV (1964). Induction of sarcomata in rabbits by intramuscular injection of iron dextran. Br Med J 1: 1593-4.
62. Hann H-WL, Levy HM, Evans AE (1980). Scrum ferritin as a guide to therapy in neuroblastoma. Cancer Res 40: 1411-3.
63. Hann H-WL, Evans AE, Cohen IJ, Leitmeyer BA (1981). Biologic differences between neuroblastoma stages IV-S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 305: 425-9.
64. Hann H-WL, Stahlhut MW, Millman I (1984). Human ferritins present in the sera of nude mice transplanted with human neuroblastoma or hepatocellular carcinoma. Cancer Res 44: 3898-901.
65. Hann H-WL, Evans AE, Siegel SE et al (1985). Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the children's cancer study group experience. Cancer Res 45: 2843-8.
66. Hann HW-L, Stahlhut NW, Blumberg BS (1988). Iron nutrition and tumor growth: decreased growth in iron-deficient mice. Cancer Res 48: 4168-70.
67. Hann H-WL, Kim CY, London WT, Blumberg BS (1989). Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer 43: 376-9.
68. Hann H-WL, Lange B, Stahlhut MW, McGlynn KA (1990a). Prognostic importances of serum transferring and ferritin in childhood Hodgkin's disease. Cancer 66: 313-6.
69. Hann H-WL, Stahlhut MW, Hann CL (1990b). Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11: 566-9.
70. Hann H-WL, Stahlhut MW, Menduke H (1991). Iron enhances tumor growth. Cancer 68: 2407-10.
71. Hann H-WL, Stahlhut MW, Rubin R, Maddrey WC (1992). Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70: 2051-6.
72. Hardy JA, Aust AE (1995). Iron in asbestos chemistry and carcinogenicity. Chem Rev 95: 97-118.
73. Herbert V, Shaw S, Jayatilleke E (1995). Serum ferritin-iron (holoferritin): the first reliable (not confounded by inflammation) serum measure of body iron stores. J Invest Med 43 (Suppl 1): 198A.
74. Herrinton LJ, Friedman GD, Baer D, Selby JV (1995). Transferrin saturation and risk of cancer. Am J Epidemiol 142: 692-708.
75. Hibbs JB Jr, Taintor RR, Vavrin Z (1984). Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem Biophys Res Commun 123: 716-21.
76. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM (1988). Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157: 87-94.
77. Hibbs JB Jr, Westenfelder C, Taintor R et al (1992). Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89: 867-77.
78. Holley RW (1972). A unifying hypothesis concerning the nature of malignant growth. Proc Natl Acad Sci USA 69: 2840-1.
79. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr (1995). Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60: 160-2.
80. Iancu TC (1989). Iron and neoplasia: ferritin and hemosiderin in tumor cells. Ultrastruct Pathol 13: 573-84.
81. Icso J, Szollosova M, Sorahan T (1994). Lung cancer among iron ore miners in east Slovakia: a case control study. Occup Environ Med 51: 642-3.
82. Israel JL, McGlynn KA, Hann H-WL, Blumberg BS (1989). Iron-related markers in liver cancer. In Iron in Immunity, Cancer and Inflammation (eds de Sousa M, Brock JH); J Wiley, Chichester, pp. 301-16.
83. Jacobs A, Jones B, Ricketts C, Bulbrook RD, Wang DY (1976). Serum ferritin concentration in early breast cancer. Br J Cancer 34: 286-90.
84. Jacobs P, Bothwell T, Charlton RW (1964). Role of hydrochloric acid in iron absorption. J Appl Physiol 19: 187-8.
85. Jagadeesan V, Jayanthi RN, Sesikeran B (1994). Effect of iron deficiency on DMH-induced gastrointestinal tract tumors and occurrence of hepatocyte abnormalities in Fischer rats. Nutr Cancer 22: 285-91.
86. Kamp DW, Graceffa P, Pryor WA, Weitzman SA (1992). The role of free radicals in asbestos-induced diseases. Free Rad Biol Med 12: 293-315.
87. Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA (1995). Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalysed free radicals. Am J Physiol 268: L471-80.
88. Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA, Naumann PW (1990). Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76: 991-5.
89. Kemp JD, Smith KM, Mayer JM, Gomez F, Thorson JA, Naumann PW (1992). Effects of anti-transferring receptor antibodies on the growth of neoplastic cells. Pathobiology 60: 27-32.
90. Kew MD (1990). Pathogenesis of hepatocellular carcinoma in hereditary hemoehromatosis: occurrence in noncirrhotic patients. Hepatology 11: 1086-7.
91. Kikendall JW, Bowen PE, Burgess MB, Magnetti C, Woodward J, Langenberg P (1989). Cigarettes and alcohol as independent risk factors for colonie adenomas. Gastroenterology 97: 660-4.
92. Klatsky AL, Armstrong MA, Friedman GD, Hiatt RA (1988). The relations of alcoholic beverage use to colon and rectal cancer. Am J Epidemiol 128: 1007-15.
93. Kletter G, Parks BR Jr, Bhatnager A, Iter RV (1988). Elevated serum iron levels following administration of cisplatinum. Onology 45: 421-3.
94. Knekt P, Reuanen A, Takkunen H, Aromas A, Heliovaara M, Hakulinen T (1994). Body iron stores and risk of cancer. Int J Cancer 56: 379-82.
95. Konijn AM, Hershko C (1989). The anaemia of infection and chronic disease. In Iron in Immunity, Cancer and Inflammation (eds de Sousa M, Brock JH); J Wiley & Sons, Chichester, pp. 111-44.
96. Kontoghiorghes GJ, Weinberg ED (1995). Iron: mammalian defence systems, mechansims of disease and chelation therapy approaches. Blood Rev 9: 33-45.
97. Laires A, Borba H, Rueff J, Gomes MI, Halpern M (1982). Urinary mutagenicity in occupational exposure to mineral oils and iron oxide particles. Carcinogenesis 3: 1077-9.
98. Langvaad E (1968). Iron dextran induction of distant tumors in mice. Im J Cancer 3: 415-23.
99. Lauffer RB (1992). Preventive measures for the maintenance of low but adequate iron stores. In Iran and Human Disease (ed Lauffer RB); CRC Press, Boca Raton, FL, pp. 459-76.
100. Ledue TB, Craig WY (1995). Serum concentrations of transferrin receptor in hereditary hemochromatosis. Clin Chem 41: 1053-4.
101. Lee GR (1983). The anemia of chronic disease. Semin Hematol 20: 61-80.
102. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE (1991). Dietary effects on breast cancer risk in Singapore. Lancet 337: 1197-200.
103. Lepoivre M, Flaman J-M, Bobé P, Lemaire G, Henry Y (1994). Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. J Biol Chem 269: 21891-7.
104. Levin B (1988). Neoplasms of the large and small intestine. In Cecil's Textbook of Medicine 18th ed. (eds Wyngaarden JB, Smith LH Jr, Bennett JC); WB Saunders, Philadelphia, pp. 713-21.
105. Li J-L, Okada S, Hamazaki S, Ebina Y, Midorikawa O (1987). Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacatetate. Cancer Res 47: 1867-9.
106. Locke A, Main HR, Rosbach DO (1932). The copper and non-hemoglobinous iron contents of the blood serum in disease. J Clin Invest 11: 527-42.
107. Loughlin KR, Gittes RF (1986). Serum iron: a tumour marker in renal carcinoma. Br J Urol 58: 617-20.
108. Luce D, Brochard P, Quenel P et al (1994). Malignant pleural mesothelioma associated with exposure to tremolite. Lancet 344: 1777.
109. Lund LG, Aust AE (1991). Iron-catalysed reactions may be responsible for the biochemical and biological effects of asbestos. Bio Factors 3: 83-9.
110. Lund LG, Aust AK (1992). Iron mobilization from crocidolite asbestos greatly enhances crocidolite-depedent formation of DNA single-strand breaks in X174 FRI DNA. Carcinogenesis 13: 637-42.
111. Lundberg JH, Chitambar CR (1990). Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukaemic HL60 cells. Cancer Res 50: 6466-70.
112. Lundin PM (1961). The carcinogenic action of complex iron preparations. Br J Cancer 15: 838-47.
113. Lustbader ED, Hann H-W L, Blumberg BS (1983). Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 220: 423-5.
114. Magnusson G, Flodh H, Malmfors T (1977). Oncological study in rats of Ferastral, an iron-poly (sorbitol-gluconic acid) complex after intramuscular administration. Scand J Haematol Suppl 32: 87-98.
115. Marcus DM, Zinberg N (1975). Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J Natl Cancer Inst 55: 791-4.
116. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnock JS (1988). Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 27:8708-11.
117. Martin JHJ, Edwards SW (1993). Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. J Immunol 150: 3478-82.
118. Mazzanti R, Srai KS, Debnam ES, Boss AM, Gentilini P (1987). The effect of chronic ethanol consumption on iron absorption in rats. Alcohol Alcohol 22: 47-52.
119. McCord JM (1992). Iron and oxidative balance. In Iron and Human Disease (ed Lauffer RB); CRC Press, Boca Raton, FL, pp. 509-18.
120. McGowan SE, Henley SA (1988). Iron and ferritin contents and distribution in human alveolar macrophages. J Lab Clin Med 111: 611-17.
121. Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Bjorkholm M (1990). The incidence of cancer among blood donors. Int J Epidemiol 19: 505-9.
122. Meyer B, Muller F, Luus H, Lotter T (1992). Faecal blood loss associated with aspirin and pentoxifylline, given alone and in combination. Drug Invest 4: 215-8.
123. Mihas AA, Tavassoli M (1991). The effect of ethanol on the uptake, binding and desialylation of transferrin by rat liver endothelium: implications in the pathogenesis of alcohol-associated hepatic siderosis. Am J Med Sci 301: 229-304.
124. Milman N, Sengelov H, Dombernowsky P (1991). Iron status markers in patients with small cell carcinoma of the lung. Relation to survival. Br J Cancer 64: 895-8.
125. Moore PS, Chang Y (1995). Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332: 1181-5.
126. Moreno JJ, Foroozesh M, Church DF, Pryor WA (1992). Release of iron from ferritin by aqueous extracts of cigarette smoke. Chem Res Toxicol 5: 116-23.
127. Morgan EH, Iacopetta BJ (1987). Vinblastine but not other microtubule inhibitors block transferrin endocytosis and iron uptake by reticulocytes. Clin Exp Pharmacol Physiol 14: 119-26.
128. Mussalo-Rauhammas H, Salmela SS, Leppanen A, Pyysalo H (1986). Cigarettes as a source of some trace and heavy metals and pesticides in man. Arch Environ Health 41: 49-55.
129. Neckers LM (1984). Transferrin receptors regulate proliferation of normal and malignant B cells. Curr Top Micro Immunol 113: 62-8.
130. Neglia JP, Wileisnsji CL, Warwick WJ (1991). Cancer risk among patients with cystic fibrosis. J Pediatr 119: 764-6.
131. Nelson RL (1992). Dietary iron and colorectal cancer risk. Free Rad Biol Med 12: 162-3.
132. Nelson RL, Yoo SJ, Tanure JC, Andianopoulos G, Misumi A (1989). The effect of iron on experimental colorectal carcinogenesis. Anticancer Res 9: 1477-82.
133. Nelson RL, Davis FG, Sutter E, Sobin LH, Kikendall JW, Bowen P (1994). Body iron stores and risk of colonie neoplasia. J Natl Cancer Inst 86: 455-60.
134. Nelson RL, Davis FG, Persky V, Becker E (1995). Benign and malignant disease in hereditary hemochromatosis heterozygotes. Cancer 76: 875-9.
135. Nettesheim P, Creasia DA, Mitchell TJ (1975). Carcinogenic and cocarcinogenic effects of inhaled synthetic smog and ferric oxide. J Natl Cancer Inst 55: 159-70.
136. Neugut AI, Garbowski GC, Lee WC et al (1993). Dietary risk factors for the incidence and recurrence of colorectal adenomatous polyps. Ann Intern Med 118: 91-5.
137. Neumannova V, Richardson DR, Kriegerbeckova K, Kovar J (1995). Growth of human tumor cell lines in transferrin-free, low iron medium. In Vitro Cell Dev Biol 31: 625-32.
138. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampish HJ, Strohmeyer G (1985). Survival and causes of death in cirrhosis and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313: 1256-62.
139. Okada S, Hamazaki S, Toyokuni S, Midorikawa O (1989). Induction of mesothelioma by intraperitoneal injection of ferric saccharate in male Wistar rats. Br J Cancer 60: 708-11.
140. Or R, Matzner Y, Konijn AM (1987). Serum ferritin in patients undergoing bone marrow transplantation. Cancer 60: 1127-31.
141. Potaznik D, Groshen S, Miller D et al (1987). Association of serum iron, serum transferrin saturation, and serum ferritin with survival in acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 9: 350-5.
142. Price VE, Greenfield RE (1958). Anemia in cancer. Adv Cancer Res 5: 199-290.
143. Prime SS, MacDonald DG, Rennie JS (1983). The effect of iron deficiency on experimental oral carcinogenesis in the rat. Br J Cancer 47: 413-8.
144. Qian M, Eaton JW (1989). Tobacco-borne siderophoric activity. Arch Biochem Biophys 275: 280-8.
145. Reid TM, Loeb LA (1982). Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res 52: 1082-6.
146. Richmond HG (1959). Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1: 947-9.
147. Ritland S, Aaseth J (1987). Trace elements and the liver. J Hepatol 5: 118-22.
148. Robertson AG, Dick WC (1977). Intramuscular iron and local oncogenesis. Br Med J 1: 946.
149. Roe JFC, Haddow A, Dukes CE, Mitchly BCV (1964). Iron-dextran carcinogenesis in rats. Br J Cancer 18: 801-8.
150. Rohan TE, McMichael AJ (1988). Alcohol consumption and risk of breast cancer. Int J Cancer 41: 695-9.
151. Saffiotti U, Montesano R, Sellakumar AR, Cefis F, Kaufman DG (1972). Respiratory tract carcinogenesis in hamsters induced by different numbers of administrations of benza(α)pyrene and ferric oxide. Cancer Res 32: 1073-81.
152. Sahu SC (1992). Dietary iron and cancer: a review. Environ Carcinog Ecotoxicol Rev C10: 205-37.
153. Seligman PA, Schleicher RB, Siriwardana G, Domenico J, Gelfand EW (1993). Effects of agents that inhibit cellular iron incorporation on bladder cell proliferaiton. Blood 82: 1608-17.
154. Sethi VS, Shihabi Z, Spurr CL (1984). Increase of serum iron concentrations in Rhesus monkeys and humans on administration of vincristine, vinblastine or vindesine. Cancer Treat Rev 68: 933-6.
155. Sherson D, Svane O, Lynge E (1991). Cancer incidence among foundry workers in Denmark. Arch Environ Health 46: 75-81.
156. Shterman N, Kupfer B, Moroz C (1991). Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59: 19-25.
157. Siegers C-P, Bumann D, Baretton G, Younes M (1988). Dietary iron enhances the tumor rate in dimethylhydrazine-induced colon carcinogenesis in mice. Cancer Lett 41: 251-6.
158. Siegers C-P, Bumann D, Baretton G (1991). The effect of desferrioxamine on cell proliferation in human tumour cell lines. Toxicol In Vitro 5: 427-30.
159. Singh M, Lu J, Briggs SP, McGinley JN, Haegele AD, Thompson HJ (1994). Effect of excess dietary iron on the promotion stage of 1-methyl-1-nitrosourea-induced mammary carcingoenesis: pathogenetic characteristics and distribution of iron. Carcinogenesis 15: 1567-70.
160. Smith AG, Cabrai JRP, Carthew P, Francis JE, Manson MM (1989). Carcinogenicity of iron in conjunction with a chlorinated environmental chemical, hexachlorobenzene, in C57BL/10ScSn mice. Int J Cancer 43: 492-6.
161. Smith AG, Francis JE, Carthew P (1990). Iron as a synergist for hepatocellular carcinoma induced by polychlorinated biphenyls in Ah-responsive C57BL/10ScSn mice. Carcinogenesis 11: 437-44.
162. Sorokin LM, Morgan EH, Yeoh GCT (1989). Transformation-induced changes in transferrin and iron metabolism in myogenic cells. Cancer Res 49: 1941-7.
163. Spear AT, Sherman AR (1992). Iron deficiency alters DMBA-induced tumor burden and natural killer cell cytotoxicity in rats. J Nutr 122: 46-55.
164. Stevens RG (1990). Iron and the risk of cancer. Med Oncol Tumor Pharmacother 7: 177-81.
165. Stevens RG (1992). Iron and cancer. In Iron and Human Disease (ed Lauffer RB); CRC Press, Boca Raton, FL, pp. 333-47.
166. Stevens RG, Beasley RP, Blumberg BS (1986). Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 76: 605-10.
167. Stevens RG, Jones DY, Micozzi MS, Taylor PR (1988). Body iron stores and the risk of cancer. N Engl J Med 319: 1047-52.
168. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS (1994). Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 56: 364-9.
169. Strain JJ (1994). Putative role of dietary trace elements in coronary heart disease and cancer. Br J Biomed Sci 51: 241-51.
170. Sussman HH (1992). Iron in cancer. Pathobiology 60: 2-9.
171. Taetle R, Honeysett JM, Bergeron R (1989). Combination iron depletion therapy. J Natl Cancer Inst 81: 1229-35.
172. Tartter PI (1989). Does blood tranfusion predispose to cancer recurrence? Am J Clin Oncol 12: 169-71.
173. Thompson AB, Bohling T, Heires A, Under J, Rennard SI (1991a). Lower respiratory tract iron burden is increased in association with cigarette smoking. J Lab Clin Med 117: 493-9.
174. Thompson HJ, Kennedy K, Witt M, Juzefyk J (1991b). Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis 12: 111-4.
175. Thun MJ, Namboodiri MM, Heath CW Jr (1991). Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-6.
176. Timeus F, Valle P, Crescenzio N et al (1994). Effect of desferrioxamine and hydroxypyridones on hemopoietic progenitors and neuroectodermal tumor cells. Am J Hematol 47: 183-8.
177. Tonz O, Weiss S, Strahm HW, Rossi E (1965). Iron absorption in cystic fibrosis. Lancet ii: 1096-9.
178. Toyokuni S, Sagripanti J-L (1992). Iron-mediated DNA damage: sensitive detection of DNA strand breakage catalysed by iron. J Inorgan Biochem 47: 241-8.
179. Turlin B, Juguet F, Moirand R et al (1995). Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22: 446-50.
180. Turner HM, Grace HG (1938). An investigation into cancer mortality among males in certain Sheffield trades. J Hyg 38: 90-103.
181. Ullah A, Shamsuddin AM (1990). Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis 11: 2219-22.
182. Van Asperen IA, Feskens EJM, Bowles CH, Kromhout D (1995). Body iron stores and mortality due to cancer and ishcaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 24: 665-70.
183. Vostrejs M, Moran PL, Seligman PA (1988). Transferrin synthesis by small cell lung cancer acts as an autocrine regulator of cellular proliferation. J Clin Invest 82: 331-9.
184. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER (1988). Neopterin as marker for activation of cellular immunity: immunologie basis and clinical application. Adv Clin Chem 27: 81-141.
185. Webster DJT (1981). Tumour induction by carcinogens in iron deficient rats. Anticancer Res 1: 293-4.
186. Weinberg ED (1981). Iron and neoplasia. Biol Trace Elem Res 3: 55-80.
187. Weinberg ED (1984). Iron withholding: a defence against infection and neoplasia. Physiol Rev 64: 65-102.
188. Weinberg ED (1989). Iron, asbestos and carcinogenicity. Lancet i: 1399-400.
189. Weinberg ED (1992a). Roles of iron in neoplasia: promotion, prevention and therapy. Biol Trace Elem Res 34: 123-40.
190. Weinberg ED (1992b). Roles of iron in functions of activated macrophages. J Nutr Immunol 1: 41-63.
191. Weinberg ED (1992c). Iron depletion: a defence against intracellular infection and neoplasia. Life Sci 50: 1289-97.
192. Weinberg ED (1993). Association of iron with respiratory tract neoplasia. J Trace Elem Exp Med 6: 117-23.
193. Weinberg ED (1994a). Role of iron in colorectal cancer. Bio Metals 7: 211-6.
194. Weinberg GA (1994b). Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 38: 997-1003.
195. Weinberg JB, Hibbs JB Jr (1977). Endocytosis of red blood cells or hemoglobin by activated macrophages inhibits their tumorcidal effect. Nature 269: 245-7.
196. Wesselius LJ, Flowers CH, Skikne BS (1992). Alveolar macrophage content of isoferritins and transferrin. Am Rev Respir Dis 145: 311-16.
197. Wesselius LJ, Nelson ME, Skikne BS (1994). Increased release of ferritin and iron by iron-loaded macrophages in cigarette smokers. Am J Respir Crit Care Med 150: 690-5.
198. Wharton M, Granger DL, Durack DT (1988). Mitochondrial iron loss from leukemia cells injured by macrophages. J Immunol 141: 1311-7.
199. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE (1990). Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 323: 1664-71.
200. Wu AH, Paganini-Hill A, Ross RK (1987). Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 55: 687-94.
201. Yarbro JW (1992). Mechanisms of action of hydroxyurea. Semin Oncol 19: 1-10.
202. Yoshiji H, Nakae D, Kinugasa T et al (1991). Inhibitory effect of dietary iron deficiency on the induction of putative preneoplastic foci in rat liver initiated with diethylnitrosoamine and promoted by phenobarbital. Br J Cancer 64: 839-42.
203. Zhou X-D, Detolla L, Custer RP, London WT (1987). Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer 59: 1430-7.
204. Ziegler JL (1993). Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 342: 1348-51.